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Small cell lung cancer (SCLC) is a devastating tumor type with great therapeutic need. In this issue of Cancer
Cell, Christensen and colleagues identify THZ1, a CDK7 inhibitor, as a potential therapy for SCLC. Using cells
and mouse models, the authors show exquisite sensitivity of SCLC to transcriptional inhibition.Small cell lung cancer (SCLC) is a neuro-
endocrine tumor type that represents
15% of lung cancer diagnoses. SCLC
is typically metastatic when diagnosed
and is considered the deadliest lung can-
cer subtype with an overall 5-year survival
of less than 5%. Although SCLC is typi-
cally very responsive to chemotherapy,
the response is short lived, and chemore-
fractory SCLC almost invariably emerges.
In contrast to non-small cell lung cancer
(NSCLC), for which a number of targeted
therapies are available, SCLC has not
seen substantial improvements in thera-
pies over the past four decades, and no
approved targeted therapies exist for
SCLC. Next-generation sequencing ana-
lyses highlight a complex genomic land-
scape in SCLC with high numbers of pro-
tein-altering mutations (Peifer et al., 2012;
Rudin et al., 2012). However, low numbers
of SCLC samples have been sequenced
to date relative to other major cancers,
and clear SCLC-mutated drug targets
have not yet emerged. With the focus of
the translational lung cancer research
community almost entirely on NSCLC,
targeted therapies for SCLC have lagged
behind the need.
To address the need for improved
SCLC therapies, Christensen et al. (2014
in this issue of Cancer Cell) screened
over 1,000 experimental and clinical com-
pounds for efficacy across three murine
SCLC (mSCLC) cell lines. The cell lines
were isolated from a genetically engi-
neered mouse (GEM) model for SCLC
that is based on deletion of Rb and p53
in the lung epithelium; this model recapit-
ulates the key features of human SCLC
(Meuwissen et al., 2003). Of screen
hits that included cell cycle inhibitors,
mTOR-PI3-kinase pathway inhibitors,
and transcriptional inhibitors, the authorsfocused their attention on THZ1, a tran-
scriptional inhibitor that acts by forming
a covalent interaction with CDK7. The au-
thors found that SCLC lines were 5-fold
more sensitive to THZ1 growth inhibition
than NSCLC cell lines.
CDK7 regulates transcription initia-
tion by phosphorylating the C-terminal
domain of RNA polymerase II. CDK7 is
also a component of the CDK activating
kinase that controls activation of the cell
cycle by driving cyclin-dependent ki-
nases, including CDK1 and CDK2. THZ1
forms a covalent link to a cysteine residue
located outside the CDK7 canonical
kinase domain to irreversibly inactivate
CDK7 (Kwiatkowski et al., 2014). A previ-
ous study found that THZ1 treatment led
to potent antiproliferative effects in T cell
acute lymphoblastic leukemia cells and
xenografts (Kwiatkowski et al., 2014).
Christensen et al. (2014) followed up on
their observations of THZ1 sensitivity in
SCLC cell lines to investigate THZ1 effi-
cacy in vivo using the autochthonous
SCLC GEM model (Meuwissen et al.,
2003). Using MRI to image SCLC tumor
volume at baseline and following treat-
ment, they report that THZ1 resulted in
reduced tumor progression and, in some
cases, dramatic tumor regression. THZ1
treatment also extended survival of
animals with mSCLC. THZ1 treatment
showed in vivo effects in the model com-
parable to that found for the standard
chemotherapeutic regimen (cisplatin/eto-
poside). Finding a targeted therapeutic
that could be added to a cisplatin/
etoposide chemotherapy regimen might
harness the chemosensitivity seen in
human SCLC and lead to a durable pa-
tient response. Unfortunately, combining
THZ1 with cisplatin/etoposide did not
result in a stronger tumor regressionCancer Cell 26,than either drug regimen alone. However,
THZ1 was effective in xenograft models
that were generated from chemorefrac-
tory cell lines, suggesting potential for ef-
ficacy in human chemorefractory SCLC.
Importantly, in contrast to cisplatin/eto-
poside treatment in mice, THZ1 treat-
ment was not associated with detectable
toxicity.
The authors next investigated the
underlining mechanisms associated with
THZ1 sensitivity in SCLC. Among the top
differentially expressed transcripts upon
THZ1 treatment in SCLC cell lines were
genes associated with transcription.
In previous work from this group, THZ1
preferentially reduced the expression of
genes associated with a subtype of tran-
scriptional enhancers termed ‘‘super-en-
hancers’’ (Kwiatkowski et al., 2014).
Typical enhancers are composed of tran-
scription factor binding sites located at a
distance from the transcriptional start
site that act through chromosomal loop-
ing events to enhance transcription.
Super-enhancers consist of very large
clusters of enhancers and have been
associated with highly expressed genes
that confer cell identity (Whyte et al.,
2013), and, in cancer cells, include onco-
genes (Love´n et al., 2013).
The authors mapped enhancers and
super-enhancers in three human SCLC
lines by performing ChIP-seq analyses
against acetylated lysine 27 of histone
H3. An average of 100 super-enhancer
associated genes were identified in the
SCLC cell lines, including genes encoding
oncogenic transcription factors such as
MYC family members (MYC and MYCN),
SOX2, andNFIB. Genes encoding lineage
transcription factors such as INSM1,
ASCL1, and NEUROD1 were also identi-
fied as harboring super-enhancers orDecember 8, 2014 ª2014 Elsevier Inc. 783
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Previewsatypically large enhancers in SCLC.
Moreover, transcripts reduced upon
THZ1 treatment were enriched for those
whose genes contain super-enhancers,
including MYC members, NFIB, and line-
age transcription factors. Thus, candidate
mediators of THZ1 response in SCLC
include oncogenic and neuroendocrine
lineage transcription factors.
Christensen et al. (2014) have identified
a promising candidate drug for potential
clinical usewith strong antiproliferative ef-
fects in both chemo-naive and chemore-
fractory SCLC. It is not yet clear whether
subsets of SCLC patients may preferen-
tially benefit from treatment with THZ1
or other transcriptional inhibitors. In cell
culture, THZ1 was widely effective across
SCLC cell lines regardless of what
specific genes were mutated, but, in vivo,
THZ1 treatment resulted in strikingly
different responses in different animals.
Three of nine THZ1-treated mice had
remarkable responses to THZ1 treatment
while other animals showed little effect or
exhibited stable disease without tumor
regression. One major question that re-
sults from the work is: what confers sensi-
tivity of SCLC to THZ1 treatment in vivo?
SCLC in the mouse model is simpler
genetically than human SCLC but still
exhibits spontaneous and heterogeneous
secondary alterations, such as high
level Mycl1 or Nfib gene amplifications
(McFadden et al., 2014). It would be inter-
esting for future studies to link secondary784 Cancer Cell 26, December 8, 2014 ª201alterations that occur in the model to
THZ1 response in vivo. THZ1was recently
shown to be particularly effective in the
context of MYCN-amplified neuroblas-
toma (Chipumuro et al., 2014) and may
be broadly effective in MYC family ampli-
fied tumors.MYCL1 is themost frequently
amplified MYC member in SCLC, and
it would be interesting to determine
whether a more homogeneous in vivo
response to THZ1 might be obtained in
an SCLC mouse model driven by Mycl1
overexpression (Huijbers et al., 2014).
Christensen et al.’s work also draws
attention to genes encoding neural/
neuroendocrine lineage transcription fac-
tors, such as ASCL1, NEUROD1, and
INSM1 that were sensitive to transcrip-
tional inhibition using THZ1. Roles for
such factors in THZ1 response need to
be explored, because transcription fac-
tors controlling neuroendocrine cell state
may themselves reflect therapeutic vul-
nerabilities in SCLC.
The identification of effective therapies
for SCLC remains a major challenge.
However, this work opens up a novel
avenue in the exploration of transcrip-
tional inhibitors as potential new treat-
ments for SCLC.
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